The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 18, 2020
Filed:
Nov. 18, 2014
Applicants:
Eric J. Sundberg, Baltimore, MD (US);
Beatriz Trastoy Bello, Bilbao, ES;
Inventors:
Eric J. Sundberg, Baltimore, MD (US);
Beatriz Trastoy Bello, Bilbao, ES;
Assignee:
UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C12P 21/06 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12P 21/02 (2006.01); C07K 1/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/00 (2013.01); C07K 16/2887 (2013.01); C07K 16/32 (2013.01); C12P 21/02 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/71 (2013.01); C07K 2317/92 (2013.01);
Abstract
Means for improving the effector functions of current immunotherapeutic antibodies through targeted hyper-glycosylation of the antibody Fc region are disclosed, as well as antibody variants having hyper-glycosylated Fc regions. Fc receptor-mediated effector functions have been shown to be a critical contributor to the efficacies of numerous therapeutic antibodies currently in clinical use. Targeted hyper-glycosylation of antibodies has the potential to significantly improve current immunotherapies for cancer.